Latest Period
Q2 2026
Security Snapshot
Kailera Therapeutics, Inc. - Common Stock, $0.00001 par value (KLRA) Institutional Ownership
CUSIP: 482931102
13F Institutional Holders and Ownership History for Q2 2026
Institutions Reporting
99
Shares (Excl. Options)
116,014,320
Price
$22.03
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.00001 par value
- Symbol
- KLRA on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 116,014,320
- Total 13F value
- $2,555,770,785
- Portfolio coverage rank
- 0.01%
- Share change
- +115,036,463
- Value change
- +$2,534,272,284
- Number of holders
- 99
- Shares outstanding
- 129,841,205
- SEC-reported price per share
- $17.05
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- KLRA - Kailera Therapeutics, Inc. - Common Stock, $0.00001 par value is tracked under CUSIP 482931102.
- 99 institutions reported positions in Q2 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Latest quarter on this page is Q2 2026.
- Additional quarter-over-quarter change detail appears as history expands.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 99 institutions filings for Q2 2026.
Security key
482931102
Latest holder period
Q2 2026
13F holders
99
13D/G owners
3
CIK / CUSIP context first
Open Q2 2026 holders
KLRA full holder history
Kailera Therapeutics, Inc. SEC filings
Kailera Therapeutics, Inc. company facts
Kailera Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 482931102:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
KLRA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 8.9% | $238,065,120 | 11,511,853 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 30 Jun 2026 | |||
| RTW INVESTMENTS, LP | 8.3% | $222,864,638 | 10,776,820 | RTW Investments, LP | 30 Jun 2026 | |||
| CANADA PENSION PLAN INVESTMENT BOARD | 5.6% | $151,060,948 | 7,304,688 | CPP Investment Board Private Holdings (4) Inc. | 30 Jun 2026 |
As of 30 Jun 2026, 99 institutional investors reported holding 116,014,320 shares of Kailera Therapeutics, Inc. - Common Stock, $0.00001 par value (KLRA). This represents 89% of the company’s total 129,841,205 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
85%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Bain Capital Investors LLC | 20% | 26,255,581 | 12% | $578,410,449 | |
| Bain Capital Life Sciences Investors, LLC | 17% | 22,583,268 | 30% | $497,509,394 | |
| RTW INVESTMENTS, LP | 8.3% | 10,776,820 | 2% | $237,413,345 | |
| CANADA PENSION PLAN INVESTMENT BOARD | 5.6% | 7,304,688 | 0.09% | $160,922,277 | |
| Atlas Venture Life Science Advisors, LLC | 4% | 5,171,282 | 13% | $113,923,342 | |
| FMR LLC | 3.1% | 3,970,865 | 0% | $87,478,156 | |
| BlackRock, Inc. | 3% | 3,928,604 | 0% | $86,547,146 | |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.7% | 3,534,410 | 0.01% | $77,864,000 | |
| CITADEL ADVISORS LLC | 2.5% | 3,240,787 | 0.04% | $71,394,538 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.5% | 3,208,286 | 0.1% | $70,678,541 | |
| WELLINGTON MANAGEMENT GROUP LLP | 2.2% | 2,919,110 | 0.01% | $64,307,994 | |
| Royalty Pharma Sub-Manager, LLC | 1.9% | 2,455,357 | 22% | $54,091,515 | |
| Siren, L.L.C. | 1.7% | 2,214,286 | 0.99% | $48,780,721 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.3% | 1,693,958 | 0% | $37,317,895 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.3% | 1,652,507 | 0% | $36,404,729 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.87% | 1,133,115 | 0% | $24,968,475 | |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 0.85% | 1,100,000 | 0.14% | $24,233,000 | |
| Frazier Life Sciences Management, L.P. | 0.85% | 1,100,000 | 0.53% | $24,233,000 | |
| Trails Edge Capital Partners, LP | 0.76% | 984,786 | 3.4% | $21,694,836 | |
| UBS Group AG | 0.75% | 972,683 | 0% | $21,428,206 | |
| Jupiter Topco LLC | 0.75% | 970,857 | 0% | 0.01% | $21,344,291 |
| AMERIPRISE FINANCIAL INC | 0.63% | 821,331 | 0% | $18,093,970 | |
| Deep Track Capital, LP | 0.54% | 700,000 | 0.23% | $15,421,000 | |
| EVENTIDE ASSET MANAGEMENT, LLC | 0.47% | 616,720 | 0.18% | $13,586,342 | |
| Vestal Point Capital, LP | 0.44% | 575,000 | 0.3% | $12,667,250 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
1
Latest
Q2 2026
Rows shown
1-1 of 1
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 116,014,320 | $2,555,770,785 | +$2,534,272,284 | $22.03 | 99 |